It is our great pleasure to invite you to the 7th International Chicago Lymphoma Symposium, dedicated in part to commemorating the lifelong contributions of Dr. John E. Ultmann to the study of lymphoproliferative disorders. Dr. John E. Ultmann, a pioneer in the treatment of lymphoma, devoted his life to the understanding of this disease. He was particularly known for his work on the precise staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
The John E. Ultmann Keynote Address, in conjunction with the7th International Chicago Lymphoma Symposium, has been established to honor his achievements and to look ahead at how insights in biology and classification influence novel treatment strategies. This year’s keynote will be given by Professor Philippe Solal-Celigny, M.D., Ph.D., principal investigator, Laboratorie Central d'Hematologie, Centre Jean Bernard, Le Mans, France. Professor Solal-Celigny will discuss the Prognosis in Follicular Lymphoma (FL) in the Modern Era.
Chicago is a city rich in academic tradition, and we welcome you to join us at the only dedicated lymphoma symposium in the Midwest. Given the current pace of increasing information and knowledge, there is an important need to discuss the growing body of data regarding the biology and treatment of patients with Hodgkin disease and non-Hodgkin lymphoma in a peer to peer format. Our stellar speakers’ list draws from local, national, and international expertise.
The format of the meeting includes a combination of expert presentations, interactive case discussions, poster/abstract presentations, and an opportunity for question-and-answer debates. The ICLS meeting is a 2-day meeting to be held Friday afternoon and Saturday morning/early afternoon. Friday afternoon will concentrate on the scientific and translational aspects of lymphoma, while Saturday will have a clinical focus.
The Friday portion of the meeting will include abstract/poster presentations on cutting-edge lymphoma research and will include a welcome reception. Part of Saturday’s meeting will include an academic debate discussion (pros/cons) on Purine Analogs in Indolent Lymphoma and the Management of Very High Risk DLBCL. In addition, ICLS meeting participants will be able to submit lymphoma “challenging cases” prior to the meeting that will be openly discussed among a panel of lymphoma experts.
The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows in training, oncology nurses and allied health professionals committed to the prevention, management, and elimination of lymphoma.
After attending this educational activity, participants will be able to:
- Recognize the many types of T-cell lymphoma and their natural history and prognosis.
- Discuss the treatment of peripheral T-cell lymphoma.
- Discuss the approach to a young patient with relapsed follicular lymphoma.
- Review the critical biologic pathways underlying lymphomagenesis and how they can be targeted.
- Understand the current recommendations regarding the use of PET and other imaging modalities in NHL and Hodgkin lymphoma.
We look forward to welcoming you in Chicago!
| Sonali Smith, MD Co-Chair |
Andrew Evens, DO, MS Co-Chair |
Koen van Besien, MD Co-Chair |
Page last update: February 4, 2010
